The Vanguard Group Discloses Position in Avadel Pharmaceuticals

The Vanguard Group, Inc. has disclosed its position in Avadel Pharmaceuticals plc as per Form 8.3 under the Irish Takeover Panel Act. This disclosure highlights the company's interest in relevant securities that represent 1% or more. As of November 28, 2025, Vanguard disclosed ownership of 5,578,862 ordinary shares, equivalent to 5.73% of Avadel's securities.

The disclosure indicates minor activity in share dealings, with Vanguard purchasing 1,381 shares and selling 96 shares, both at a price of 21.49 USD per share. No dealings involving cash-settled or stock-settled derivatives were reported in this update, nor were there other significant arrangements or agreements in place related to Avadel's securities.

There are no supplementary forms attached, and no additional agreements, arrangements, or understandings concerning options or derivatives have been recorded by Vanguard in this disclosure.